Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

ANI purchases nearly two dozen Teva drug products
August 2015
SHARING OPTIONS:

BAUDETTE, Minn.—ANI Pharmaceuticals Inc. has expanded its portfolio with the acquisition of 22 previously marketed generic drug products from Teva Pharmaceutical Industries Ltd. for $25 million in cash and a percentage of future gross profits from product sales. The acquired products consist of 19 solid-oral dosage products and three oral suspension products, which combined have a total market value of $650 million on a trailing 12-month basis, according to IMS Health.
 
Arthur S. Przybyl, president and CEO of ANI Pharmaceuticals, said, “This acquisition meaningfully expands our product pipeline to 68 products with a total market value of $3.9B, per IMS Health. We are pleased at the opportunity to extend our collaboration with Teva beyond the three transactions we have previously completed over the past 18 months,” adding that ANI “will be manufacturing one of the initial products out of our containment facility for potent compounds.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.